DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
Charles Turck, PharmD, BCPS, BCCCP
Brennan Spiegel, MD, MSHS
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Aline Fares, MD
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
William Oh, MD
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Jorge Nieva, MD
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Vanessa Helou, MD
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
George Laliotis, MD, MPH, MHA
TILplus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis
Jacob Sands, MD
Elaine Shum, MD
Estelamari Rodriguez, MD, MPH
Personalizing Prostate Cancer Surveillance: Insights from Canary PASS
Lisa Newcomb, PhD
Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
Gerard A. Silvestri MD, MS, Master FCCP
Anurag Singh, MD
Adam H. Fox, MD, MSc
Mariam Alexander, MD, PhD
Stratifying Advanced Endometrial Cancer: Real-World Outcomes by Molecular Subtype
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.